jao
|
|
Abstract: Translationally Controlled Tumor-associated Protein (TCTP) plays a role in a plethora of normal and cancer cell functions including cell cycle progression, cell growth and metastasis. Our previous studies showed that TCTP interacts with cellular cytoskeleton and is localized, in cell-type specific manner, on actin filaments in various types of ovarian cancer cells. Here we used small interfering RNA (siRNA) for silencing TCTP expression in human ovarian surface epithelial noncancerous cell line HIO180, ovarian carcinoma cell lines SKOV3 and OVCAR3 and analyzed effect of TCTP silencing on actin cytoskeleton and cell motility. We show that a down regulation of TCTP caused dramatic restructuring and redistribution of actin filaments in HIO180, SKOV3 and OVCAR3 cells and resulted in cell motility increase. This previously unidentified dependence of actin cytoskeleton remodeling and cell motility on TCTP level might be responsible for high metastatic potential and aggressiveness of ovarian cancer cells and will help to pinpoint novel targets for anticancer therapies.. Keywords: TCTP, siRNA, ovarian cancer cells, actin cytoskeleton, cell motility.Download Full Article |
|
|
Abstract: Objectives: Certain tumor cells pretreated with chemotherapeutic drugs become more susceptible to death by apoptosis induced by killer cells of the immune system. We examined the CD8+ cytotoxic T lymphocyte (CTL)-mediated cytotoxicity in myeloid leukemia cell lines pretreated with chemotherapeutic drugs. Methods: Peripheral blood mononuclear cells were expanded in vitro in the presence of phytohemagglutinin-P, interleukins-2 and -15. CD3+ CD8+ cells representing the CTLs were isolated using magnetic immunoselection and used in immune cytotoxicity experiments against K562 and CMK leukemia cells, pretreated with two different concentrations of cytarabine and etoposide. Results: In CMK cells pretreated with etoposide at 2 μM and 20 μM concentrations, the mean cell-mediated immune cytotoxicity rose to 21.4 ± 12.9% (p=0.09) and 23.4 ± 12.6% (p=0.046), respectively, when compared to the control value of 6.6 ± 3.8%. In CMK cells pretreated with cytarabine at 1 μM and 10 μM concentrations, the mean immune cytotoxicity rose to 14.3 ± 11.2% and 22.6 ± 15.2%, respectively, compared to the control value of 8.7 ± 6.3%, although these results did not reach statistical significance. However, a similar increase in CTL-mediated immune cytotoxicity was not observed against drug-treated K562 cells. Conclusion: This study suggests that pretreatment with chemotherapeutic drugs can render CMK leukemia cells more susceptible to immune attack by activated CTLs. Further studies are needed to explore this phenomenon, to establish an immune-enhancing effect of pretreatment with chemotherapy in the treatment of leukemia. Keywords: Leukemia, cytotoxic T lymphocytes, chemotherapy, apoptosis.Download Full Article |
|
|
Abstract: It has been shown that cancer incidence is not only a function of the size of the population at risk but is strongly associated with the turnover rate of the tissue concerned. There is a strong negative correlation between melanoma incidence and the degree of skin pigmentation, and yet the melanocyte density is the same for all races. The proposal advanced in this communication is that the probability of undergoing malignant change is critically dependent on the melanocyte turnover and that this is regulated by the pigmentation process. In melanocytes, the division rate is influenced by the process of pigment donation, probably by a mechanism whereby the continual cytoplasmic loss due to cytocrine transfer of melanosomes (termed the ‘Amputation Cycle’) inhibits replication. Consequently the turnover of melanocyte stem cells in heavily pigmented epidermis will be diminished, and this is held to account for the strong negative correlation between the degree of skin pigmentation and melanoma incidence. Download Full Article |
|
|
Abstract: Background: Breast cancer is the most common invasive cancer among women globally. Its incidence greatly varies around the world the globe. There are several estimates of breast cancer incidence from different geographical areas in Iran. In addition, no systematic reviews are available pertaining to the incidence rate of breast cancer in Iran. Therefore, the present systematic review aimed to address this epidemiological gap. Method: This systematic review was carried out based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) in January 2016. In doing so, the researchers searched Medline/PubMed, Scopus, Sciencedirect, and Google scholar for international papers and four Iranian databases (Scientific Information Database, MagIran, Iran Medex, and Iran Doc) for Persian articles. Result: A total of 427 titles were retrieved in the initial search of the databases. Further refinement and screening of the retrieved studies produced a total of 18 researches. Based on the random effect model, the Age-Standardized Rate (ASR) of breast cancer was 26.4, 95% CI (20.1 to 31.7). However, the results of Cochran’s test showed the heterogeneity of the studies (Q=1788.2, df=17, I2=99%, p<0.001). Conclusion: The incidence of breast cancer was lower in Iran compared to other parts of the world. However, establishing cancer registries covering a broader perspective of the population and carrying out further studies are needed to map out the exact incidence rate and trend of breast cancer in Iran. Keywords: Incidence, Breast cancer, Iran.Download Full Article |
|
|
Abstract: Objectives: To determine the optimal time to wait for urination ability restoration after urethral catheterization and anti – androgen treatment, in cases of acute urinary retention and advanced prostate cancer. Methods: We enrolled 26 patients with histologically confirmed prostate cancer after transrectal ultrasound guided biopsy of the prostate and CT or MRI proven advanced stages (T3-T4). We evaluated the dynamic changes of the following factors; IPSS, QoL, Vmax, residual urine, serum concentration of PSA at the following periods; before hormonal treatment, 1, 3 and 6 months after hormonal treatment. Results: How long we have to wait after urethral catheter insertion and hormonal treatment for voiding ability restoration? Our data analyses revealed the answer to this question. The dynamic changes of all the parameters (IPSS, QoL, Vmax, PSA) we studied disclosed interesting regularity. The consequent comparative analyses of parameters showed statistically significant changes only 1 month after anti – androgen treatment. These changes indicate that the prostate cancerous process is significantly suppressed within 1 month after hormonal treatment and there is no point to wait more than 1 month. Conclusion: Analyzing our data we obtained versatile evidence, that in advanced prostate cancer and acute urinary retention cases the optimal time to wait for sufficient voiding is 1 month period after permanent catheter insertion and anti – androgen treatment. Keywords: Non-small-cell lung carcinoma, EGFR, wild-type, erlotinib, second-line.Download Full Article |